Ionis Pharmaceuticals price target lowered to $82 from $85 at Wells Fargo

Wells Fargo lowered the firm’s price target on Ionis Pharmaceuticals to $82 from $85 and keeps an Overweight rating on the shares. The firm views WAINUA sales in first partial quarter of launch as encouraging given the focus on newly diagnosed segment. Wells also thinks doni can show greater benefit vs existing HAE treatments in switch study with data at EAACI.